Popular terms

Antibodies topics
Antibodies
Recombinant
Nucleic Acid
Nucleic Acids
Polypeptide
Therapeutics
Immunoglobulin
Immunoglobulins
Monoclonal
Radiation Therapy
Desmoplastic
Hypertension
Hypertensive
Immunotherapy
Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antibodies patents



      

This page is updated frequently with new Antibodies-related patent applications.




Date/App# patent app List of recent Antibodies-related patents
04/07/16
20160097784 
 Detection of polymyxins patent thumbnailDetection of polymyxins
The present invention relates to antibodies for use in detecting polymyxins and tracers; and to a single-capture immunodetection method and kits, each utilising the antibodies of the invention, and disclosed tracers.. .
Randox Laboratories Limited


04/07/16
20160097783 
 Immunoassay for pyrrolidinophenones patent thumbnailImmunoassay for pyrrolidinophenones
The current invention provides an improved immunoassay for the detection and determination of pyrrolidinophenone based designer drugs in hair and biological fluids (urine, blood, and oral fluid). The generic immunoassay is underpinned by novel, sub-family-specific antibodies, which display surprising sensitivity.
Randox Laboratories Limited


04/07/16
20160097777 
 Immunological method patent thumbnailImmunological method
The present invention relates to an in vitro method for the detection of an anti-drug antibody (ada) against a therapeutic drug antibody (tda) in a biological sample. The in vitro method comprises detecting and capturing said ada using affinity moieties obtained from an intact therapeutic drug antibody, or a fab fragment thereof, in a certain manner.
Gyros Patent Ab


04/07/16
20160097776 
 Therapeutic antibodies against ror-1 protein and methods for use of same patent thumbnailTherapeutic antibodies against ror-1 protein and methods for use of same
Therapeutic antibodies having binding specificity for ror-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ror-1 protein expressed on putative cancer cells are also provided..
The Regents Of The University Of California


04/07/16
20160097084 
 Kinase activity detection methods patent thumbnailKinase activity detection methods
A strategy to take advantage of time-resolved luminescence of ln3+-chelated phosphotyrosine-containing peptides, which facilitate efficient energy transfer to small molecule fluorophores conjugated to the peptides to produce orthogonally-colored biosensors for two different kinases is provided. The method enables multiplexed detection with high signal to noise in a high-throughput-compatible format and a platform that could be applied to other lanthanide metal and fluorophore combinations to achieve even greater multiplexing without the need for phosphospecific antibodies..

04/07/16
20160096903 
 Humanization of rabbit antibodies using a universal antibody framework patent thumbnailHumanization of rabbit antibodies using a universal antibody framework
The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications..
Esbatech, An Alcon Biomedical Research Unit Llc


04/07/16
20160096902 
 Chimeric antigen receptor-targeting monoclonal antibodies patent thumbnailChimeric antigen receptor-targeting monoclonal antibodies
Provided are monoclonal antibodies that detect cd 19 car-modified immune cells and car-modified immune cells irrespective of the tumor associated antigen they target. Methods of using these functional monoclonal antibodies include, but are not limited to, detection, quantification, activation, and selective propagation of car-modified immune cells..
Board Of Regents, The University Of Texas System


04/07/16
20160096901 
 Anti-cd38 human antibodies and uses thereof patent thumbnailAnti-cd38 human antibodies and uses thereof
The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for cd38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma.
Morphosys Ag


04/07/16
20160096899 
 Methods for treating juvenile arthritis with anti-bile salt-stimulated lipase (bssl) antibodies patent thumbnailMethods for treating juvenile arthritis with anti-bile salt-stimulated lipase (bssl) antibodies
It provides methods and pharmaceutical compositions comprising antagonists to the protein bile salt-stimulated lipase (bssl) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising bssl antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis.
Lipum Ab


04/07/16
20160096898 
 Pc33718e patent thumbnailPc33718e
The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (pcsk9). Also provided are antibodies directed to peptides, in which the antibodies bind to pcsk9.
Rinat Neuroscience Corp.


04/07/16
20160096897 

Antibodies to masp-2


The invention relates to antibodies to masp-2 and functional equivalents thereof. In particular, the invention relates to masp-2 antibodies capable of inhibiting the function of masp-2.
Helion Biotech Aps


04/07/16
20160096894 

Antibodies to insulin-like growth factor i receptor


The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor i receptor (igf-ir), which is preferably human igf-ir. The invention also relates to human anti-igf-ir antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins.
Amgen Fremont Inc.


04/07/16
20160096893 

Anti-her2 antibodies and immunoconjugates


The invention provides anti-her2 antibodies and immunoconjugates and methods of using the same.. .
Genentech, Inc.


04/07/16
20160096891 

Anti-b7-h5 antibodies and their uses


The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the b7-h5 ligand of the b7-h5:cd28h pathway, and to the uses of such molecules in the treatment and diagnosis of autoimmune disease, transplant rejection and other inflammatory diseases.. .
The Johns Hopkins University


04/07/16
20160096888 

Folate receptor 1 antibodies and immunoconjugates and uses thereof


Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided..
Immunogen, Inc.


04/07/16
20160096887 

Folate receptor 1 antibodies and immunoconjugates and uses thereof


Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided..
Immunogen, Inc.


04/07/16
20160096886 

Methods for administering anti-il-5 antibodies


The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by il-5 and excess eosinophil production, and more specifically to mabs, fabs, chimeric and humanized antibodies. More particularly, methods are provided for reducing eosinophils in a human in need thereof, which method comprises administering to said human a composition comprising at least one anti-il-5 antibody, wherein at least one anti-il-5 antibody provides a mean maximum plasma concentration of said anti-il-5 antibody of at least about 1.03±0.21 μg/ml, an area under the curve value of at least about 15.5±2.7 μg/day/ml and a serum half-life of about 16.2±2.1 days to about 21.7±2.8 days..
Glaxosmithkline Llc


04/07/16
20160096884 

Antibodies directed against amyloid-beta peptide and methods using same


antibodies directed to the c-terminal side of β-amyloid peptide and methods of using these antibodies for diagnosing and treatment of alzheimer's disease and aβ peptide associated diseases are described.. .
Rinat Neuroscience Corp.


04/07/16
20160096883 

Glioblastoma multiforme-reactive antibodies and methods of use thereof


The present disclosure is generally related to antibodies that bind specifically to glioblastoma multiforme (gbm) cells. In particular, the present disclosure provides compositions comprising human single chain or full-length antibodies that bind tumor cells.
The Regents Of The University Of California


04/07/16
20160096882 

Neutralizing molecules to influenza viruses


The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza a viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza a virus subtypes, and methods and means for making such antibodies..
Sea Lane Biotechnologies, Llc


04/07/16
20160096881 

Means and methods for producing high affinity antibodies


The invention provides means and methods for producing high-affinity antibodies against an antigen of interest, usually stable b-cell cultures.. .
Aimm Therapeutics B.v.


04/07/16
20160096880 

Human cytomegalovirus neutralizing antibodies and use thereof


The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hcmv, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hcmv gene ul products. The invention also relates to immortalized b cells that produce, and to epitopes that bind to, such antibodies and antibody fragments.
Institute For Research In Biomedicine


04/07/16
20160095942 

Carrier-antibody compositions and methods of making and using the same


Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic..
Mayo Foundation For Medical Education And Research


04/07/16
20160095921 

Combinations and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of c-c chemokine receptor 9 (ccr9) and anti-alpha4beta7 integrin blocking antibodies


Provided herein are compositions, methods and kits for treating inflammatory bowel disease (ibd) such as crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with ibd a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (ccr9) inhibitor compound and a therapeutically effective amount of an anti-α4β7 integrin antibody such as vedolizumab.
Chemocentryx, Inc.


03/31/16
20160091490 

Compositions and methods for the diagnosis of rheumatoid arthritis


The present disclosure relates to the field of molecular biology and more specifically to methods for detecting anti-carbamylated protein (anti-carp) antibodies in the serum of rheumatoid arthritis (ra) patients.. .
Leiden University Medical Center


03/31/16
20160090598 

Antisense compounds and uses thereof


The present disclosure provides compounds comprising modified oligonucleotides and anti-cd22 antibodies. Certain such modified oligonucleotides conjugated to anti-cd22 antibodies are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell.
Isis Pharmaceuticals, Inc.


03/31/16
20160090427 

Polypeptide, anti-vegf antibody, and anti-c-met/anti-vegf bispecific antibodies comprising the same


A polypeptide, an anti-vegf antibody and an anti-c-met/anti-vegf bispecific antibody, which includes the polypeptide, a pharmaceutical composition including the antibody, and a method of treating cancer using the antibody.. .
Samsung Electronics Co., Ltd.


03/31/16
20160090426 

Construction and application of bispecific antibody epcamxcd3


The present invention provides a bispecific antibody. The bispecific antibody provided by the present invention comprises a single-chain unit and a monovalent unit, wherein the single-chain unit has a specific binding capability against surface antigen cd3 of an immune cell; the monovalent unit has a specific binding capability against the surface antigen epcam of a tumor cell; the single-chain unit comprises a single-chain variable fragment scfv fused with an fc fragment; and the monovalent unit comprises a light chain and heavy chain pair.
Wuhan Yzy Biopharma Co., Ltd.


03/31/16
20160090425 

Anti-complement factor c1s antibodies and uses thereof


The present invention relates generally to the generation and characterization of neutralizing anti-c1s monoclonal antibodies. The invention further relates to the use of such anti-c1s antibodies in the detection of complement factors of the classical complement activation pathway, such as c1s.
Annexon, Inc.


03/31/16
20160090423 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


03/31/16
20160090422 

Anti-crth2 antibodies and methods of use


The invention provides anti-crth2 antibodies and methods of using the same.. .
Genentech, Inc.


03/31/16
20160090416 

Novel antibodies


The present invention relates to novel antibodies, which combine high affinity with high potency, particularly novel antibodies against a novel epitope.. .
Numab Ag


03/31/16
20160090414 

Binding proteins specific for insulin-like growth factors and uses thereof


Binding proteins, such as antibodies directed to igf-ii with cross-reactivity to igf-i and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the igf-ii with cross-reactivity to igf-i are disclosed.
Medimmune Limited


03/31/16
20160090413 

Anti-mucin antibodies for early detection and treatment of pancreatic cancer


Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human pam4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers.
Immunomedics, Inc.


03/31/16
20160090412 

Antibodies against the s100p protein for the treatment and diagnosis of cancer


The present invention relates to the use of antibodies against the s100p protein for the prevention and/or treatment of cancer; and to methods and kits for diagnosing cancer in vitro by means of detecting the levels of s100p in a biofluid, preferably with an antibody. The invention also relates to specific anti-s100p monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as to pharmaceutical compositions and conjugates containing them..
Lykera Biomed Sa


03/31/16
20160090406 

Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof


The invention relates to neuromodulatory oligomers of the amyloid-β(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers as diagnostic and therapeutics agents, for the generation of oligomer-specific antibodies and for the discovery of substances which can interact with the oligomers and in the formation thereof. Corresponding methods for the production of the antibodies and for discovery of the substances are also disclosed as are the antibodies themselves and the use of the antibodies or substances as diagnostic and therapeutic agents.
Abbvie Deutschland Gmbh & Co. Kg


03/31/16
20160089449 

Dock-and-lock (dnl) constructs for human immunodeficiency virus (hiv) therapy


The present invention concerns methods and compositions for treatment of hiv infection in a subject, utilizing a dnl complex comprising at least one anti-hiv therapeutic agent, attached to an antibody, antibody fragment or peg. In a preferred embodiment, the antibody or fragment binds to an antigen selected from gp120, gp41, cd4 and ccr5.
Ibc Pharmaceuticals, Inc.


03/31/16
20160089431 

Nanodisk-associated immunogen super polyvalent vaccines


Disclosed are compositions of matter consisting of collections of nanodisks associated with polypeptide immunogens. Each said collection contains multiple epitopes of at least one immunogen.
Shiva Science & Technology Group Llc


03/24/16
20160084859 

Detection of indazole synthetic cannabinoids


Components for enabling immunodection of indazole synthetic cannabinoids are described including immunogens, haptens, antibodies, methods and kits.. .
Randox Laboratories Limited


03/24/16
20160084855 

Compositions and methods for modulation and detection of immune and inflammatory responses


Methods for detecting inflammatory or autoimmune conditions, comprising analyzing bacterial l-serine containing lipids in a sample; and, comparing results of the analysis of the bacterial l-serine containing lipids in the sample with information on occurrence of the bacterial l-serine containing lipids in a control sample, wherein a decreased occurrence of the bacterial l-serine containing lipids in the test sample over the occurrence of bacterial l-serine containing lipids in the control sample indicates the presence of an inflammatory or an autoimmune condition, are described herein. An example of the autoimmune condition is multiple sclerosis (ms).
University Of Connecticut


03/24/16
20160084844 

Methods of identifying glycopeptides recognized by disease-associated auto-antibodies


Methods for identifying glycopeptides and more particularly glycopeptide epitopes that are specifically recognized by disease-associated auto-antibodies are provided. In some aspects the auto-antibodies are cancer-associated or autoimmune disease associated.
Glycozym, Inc.


03/24/16
20160084842 

Woven hydrogel based biosensor


A porous hydrogel sensor that is responsive to the presence of one or more target compounds in solution is synthesized based on demixing of certain molecules in the presence of a target compound. The porous hydrogel sensor may include fluorescently tagged antibodies that are noncovalently bound to the gel and then released in the presence of the target antigen.
Syracuse University


03/24/16
20160084837 

Monoclonal antibodies with specificity for fetal erythroid cells


The present invention concerns a monoclonal antibody and corresponding hybridoma cells and antigens suitable for isolating fetal cells from maternal blood. The inventive monoclonal antibody reacts with a surface antigen present on fetal red blood cells including their nucleated precursor cells, but not with surface antigens on adult erythroid cell..
Kellbenx Inc.


03/24/16
20160084821 

Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof


Methods and compositions for the diagnosis of cancer susceptibilities, defective dna repair mechanisms and treatments thereof are provided. Among sequences provided here, the fancd2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing fanconi anemia and cancer.
Oregon Health And Science University


03/24/16
20160083800 

Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligands


Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-egfr monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.. .
Merrimack Pharmaceuticals, Inc.


03/24/16
20160083765 

Method for preparing antibodies having improved properties


The present invention is directed to methods and compositions for the production of fc-containing polypeptides having improved properties and comprising mutations at positions 243 and 264 of the fc region.. .
Merck Sharp & Dohme Corp.


03/24/16
20160083698 

Lone star virus


This disclosure concerns the isolation, identification and sequencing of a unique phlebovirus, the lone star virus. Lone star virus nucleic acid molecules, proteins and antibodies are disclosed.
The United States Of America, As Represented By The Secretary, Department Of Health And Human . . .


03/24/16
20160083482 

Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma


The present invention provides, among other things, bi-specific molecules including, but not limited to, antibodies, fynomers, aptamers, fuproteins, and protein binding domains that bind both ccl2 and loxl2 and uses thereof, in particular, for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions. In some embodiments, the present invention further provides methods and compositions for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions based on the combination of mono-specific anti-ccl2 and anti-loxl2 molecules..
Shire Human Genetic Therapies Inc.


03/24/16
20160083480 

Bispecific her2 and her3 antigen binding constructs


Described herein are isolated bi-specific antigen binding constructs, e.g., antibodies. The bi-specific antigen binding constructs include two antigen binding polypeptide constructs, e.g., a fab and an scfv.
Zymeworks Inc.


03/24/16
20160083479 

Mab 2 anti-met antibody


antibodies specifically binding an epitope comprised in the α-chain of c-met, modifications, compositions and uses thereof are disclosed herein.. .
Agency For Science, Techology And Research


03/24/16
20160083476 

Production of antibody formats and immunological applications of said formats


The invention concerns antibody formats comprising vhsequence of camelidae, such as llamas; antibodies of various formats have anti-cea or anti-cd16 vh sequences thereof; vectors expressing the antibody formats, and methods for producing the same.. .
Institut Paoli Calmettes


03/24/16
20160083475 

Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods


The present invention is directed to an antigen found on the surface of rat and human pancreatic cancer cells and provides antibodies of high specificity and selectivity to this antigen as well as hybridomas secreting the subject antibodies. Methods for both the diagnosis and treatment of pancreatic cancer are also provided.

03/24/16
20160083471 

Folate receptor 1 antibodies and immunoconjugates and uses thereof


Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided..
Immunogen, Inc.


03/24/16
20160083470 

Ferroportin antibodies and methods of use


Compositions for treating disorders of iron homeostasis are provided. More particularly, anti-ferroportin antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided..
Amgen Inc.


03/24/16
20160083469 

Targeting constructs based on natural antibodies and uses thereof


The present invention provides targeted delivery methods and constructs for treating inflammatory diseases and/or detecting in vivo tissue injuries in an individual. The targeted delivery approach utilizes an antibody that recognises an epitope found to be present at sites of inflammation.
Department Of Veterans Affairs (us)


03/24/16
20160083468 

Compositions comprising antibodies to lingo or fragments thereof


Endogenous lingo-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous lingo-1 function, such anti-lingo-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction.
Biogen Ma Inc.


03/24/16
20160083467 

Anti-ghrelin antibodies and uses thereof


The present invention relates to antibodies which bind human ghrelin and their use in methods of treating or preventing reduced appetite. The invention further relates to diagnostic tools for determining whether an individual is likely to respond to a method of treating or preventing reduced appetite..
Centre Hospitalier Universitaire De Rouen


03/24/16
20160083466 

Anti-il-25 antibodies and uses thereof


The present invention provides antibodies that bind to human interleukin-25 (il-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human il-25 with high affinity.
Regeneron Pharmaceuticals, Inc.


03/24/16
20160083465 

Anti-gdf15 antibodies


Monoclonal antibodies that bind and inhibit the activity of human gdf15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human gdf15..
Aveo Pharmaceuticals, Inc.


03/24/16
20160083464 

Functional monoclonal antibody against heparin-binding epidermal growth factor-like growth factor


Two types of antibodies (35-1 antibody and 292 antibody) capable of binding to phenylalanine at position 115, isoleucine at position 117, glycine at position 140, glutamic acid at position 141, and arginine at position 142 of a human hb-egf protein were successfully obtained. Then, it was also found that these antibodies had an activity of suppressing cleavage of the human hb-egf protein, and an activity of suppressing egfr phosphorylation that would occur when the human hb-egf bound to the egfr.
Medical & Biological Laboratories Co., Ltd.


03/24/16
20160083463 

Sodium pump antibody agonists and methods of treating heart disease using the same


antibodies that are agonists of sodium pump (na+/k+ atpase; nka) activity are provided. In particular, antibodies that specifically bind epitopes on the beta-1 (β1) subunit of nka are disclosed.

03/24/16
20160083459 

Anti-inflammatory antibodies and uses therefor


The invention provides antibodies that inhibit activation of complement, which may be used to treat various inflammatory diseases or disorders.. .
Decimmune Therapeutics, Inc.


03/24/16
20160083457 

Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease


The present invention relates to methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease (cd ad). In particular, the invention relates to antibodies that bind to c.
Immuron Limited


03/24/16
20160083456 

Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy


The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration. The invention provides compositions suitable for intranasal or inhalation treatment and administration.
Contrafect Corporation


03/24/16
20160083454 

Continuous multistep process for purifying antibodies


The invention provides a three-step chromatography process for small and large-scale purification of proteins, specifically monoclonal antibodies, using only four buffer solutions made from a mother solution.. .
Sanofi


03/24/16
20160083453 

Separation of recombinant polyclonal antibody multimers with minimal separation of monomers


The invention provides a method for removing multimers from a preparation of recombinant polyclonal antibodies (rpabs) while maintaining the ratio of monomers within a narrow range. The invention provides a method of separating recombinant polyclonal antibody multimers with minimal separation of monomers comprising subjecting a mixture comprising a plurality of monoclonal antibodies to at least one separation process selected from the group consisting of multi-modal chromatography, apatite chromatography, and hydrophobic interaction chromatography thereby producing an antibody monomer preparation that is substantially free of multimers..
Medlmmune, Llc


03/24/16
20160083452 

Isolation and purification of antibodies using protein a affinity chromatography


Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise ph viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography, preferably protein a affinity, ion exchange chromatography, and hydrophobic chromatography.
Abbvie Inc.


03/24/16
20160083439 

Novel vaccines against apicomplexan pathogens


The technology provided herein generally relates to novel fusion proteins suitable as human and/or animal vaccines against parasites or pathogens of the phylum apicomplexa. In particular, the present disclosure relates to novel fusion proteins as a basis for vaccines against plasmodium parasites, including p.
Fraunhofer-gesellschaft Zur FÖrderung Der Angew Andten Forschung E.v.


03/24/16
20160083403 

Boron-containing diacylhydrazine compounds


And the pharmaceutically acceptable salts and solvates thereof, wherein a, r4, and r5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems.

03/24/16
20160082129 

Ve-ptp extracellular domain antibodies delivered by a gene therapy vector


The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis, comprising administering a nucleic acid that encodes for a tyrosine phosphatase suppressor to a subject.. .
Aerpio Therapeutics, Inc.


03/24/16
20160082120 

Methods of using anti-cd79b immunoconjugates


Provided herein are methods of treating b-cell proliferative disorders in particular follicular lymphoma and/or diffuse large b-cell lymphoma using immunoconjugates comprising anti-cd79b antibodies in combination with additional therapeutic agents.. .
Genentech, Inc.


03/24/16
20160082105 

Antibody buffering of a ligand in vivo


Compositions and methods are provided in embodiments directed to maintaining a desired concentration range of one or more drugs in a subject, and in particular embodiments to maintaining a desired drug concentration in a body compartment in a subject, based on the surprising discovery that antibodies persist in solution in body compartments such that antibody-antigen equilibrium principles can counteract drug clearance mechanisms. One or more antibodies are selected that have a dissociation constant kd that is similar to the desired drug concentration, wherein kd is independent of the affinity of the drug for a specific drug target (receptor) in the subject..
Arrowsmith Technologies Corporation


03/24/16
20160082104 

Methods and compositions for the treatment of proliferative and pathogenic diseases


The invention features peptide fragments containing domain 4 of the streptococcus intermedius intermedilysin (ily) protein and the use of these fragments to sensitize cancer cells to antibody-based anticancer treatments. The invention also features use of these fragments to treat patients infected with microbial pathogens expressing cd59 or cd59-like molecules.
President And Fellows Of Harvard College


03/24/16
20160082102 

Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus


The present invention is directed to new bifunctional compounds and methods for treating hiv infections. The bifunctional small molecules, generally referred to as arm-h's, function through orthogonal pathways, by inhibiting the gp120-cd4 interaction, and by recruiting anti-dnp antibodies to gp120-expressing cells, thereby preventing cell infection and spread of hiv.
Yale University


03/24/16
20160082101 

Horse allergen and methods


A method for performing in vitro diagnosis of type 1 allergy, comprises contacting an immunoglobulin-containing body fluid sample from a patient suspected of having type 1 allergy with an immobilized horse allergen immobilized on a solid support, and detecting the presence, in the sample, of ige antibodies specifically binding to the horse allergen, wherein the presence of such ige antibodies specifically binding to the horse allergen is indicative of type 1 allergy. A method for treatment of type 1 allergy comprises administering to an individual susceptible to such treatment, the horse allergen, or a form of the horse allergen that is modified to abrogate or attenuate its ige binding response.
Phadia Ab


03/17/16
20160077104 

Means and methods for producing anti-proteome antibodies and identifying conserved unique or differentially expressing molecules of organisms


Disclosed are methods for identifying one or more amino acid molecules and nucleic acid molecules encoding such amino acid molecules of at least two proteomes that are conserved, unique or express at higher or lower levels in at least one of the proteomes. Expression libraries are used that produce the proteome, and in one embodiment, may produce the proteome from at least one cdna expression library in one to five reactions.
Pathovacs, Incorporated


03/17/16
20160077100 

Specific detection of rat antibodies in mouse serum


D) correlating the complex formed in (b) or (c) to the concentration of the rat antibody in the sample.. .

03/17/16
20160077097 

Method of isolating circulating tumor cells


Provided are methods for detecting or isolating circulating tumor cells (ctcs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (emt) biomarker.
Duke University


03/17/16
20160077094 

Media elaborated with newly synthesized antibodies (mensa) and uses thereof


Disclosed are methods and kits for early detection of antigen exposure through the presence or absence of antigen-specific antibodies.. .
Microbplex, Inc.


03/17/16
20160077089 

Platelet allo-antigen typing and platelet antibody tests


The present invention relates to methods for the detection of human platelet alloantigens (hpas) on human platelets, methods for the detection of human antibodies against hpas, and diagnostic test devices for carrying our said methods.. .
Davos Diagnostics Ag


03/17/16
20160076009 

Antigen binding molecules with increased fc receptor binding affinity and effector function


The present invention relates to antigen binding molecules (abms). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human cd20.
Roche Glycart Ag


03/17/16
20160076002 

Bioassay for cell conditioned media


Herein is described a novel hybridoma cell line (rmh359) and its use as a cellular bioassay to determine the efficacy of cell conditioned media (ccm) as a supplement used to support cell survival and promote growth in culture. This bioassay is the first to provide a measure of ccm bioactivity in support of hybridoma cells used in the generation and production of monoclonal antibodies..
The United States Of America, As Represented By The Secretary Of Agriculture


03/17/16
20160075798 

Isoform specific anti-her4 antibodies


Compositions and methods useful for detecting and treating cancers which express the her4 jm-a isoform are disclosed.. .
Genentech, Inc.


03/17/16
20160075797 

Anti-vasa antibodies, and methods of production and use thereof


Anti-vasa antibodies (mabs), particularly humanized mabs that specifically bind to vasa with high affinity, are disclosed. The amino acid sequences of the cdrs of the light chains and the heavy chains, as well as consensus sequences for these cdrs, of these anti-vasa mabs are provided.
Ovascience, Inc.


03/17/16
20160075796 

Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38


The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for cd38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind cd38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express cd38.
Morphosys Ag


03/17/16
20160075795 

Antibodies to carcinoembryonic antigen (cea), methods of making same, and uses thereof


The present invention relates to antigen binding molecules (abms). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies or variants thereof specific for cell surface or membrane bound human cea.
Roche Glycart Ag


03/17/16
20160075794 

Antigen binding molecules with increased fc receptor binding affinity and effector function


The present invention relates to antigen binding molecules (abms). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human cd20.
Roche Glycart Ag


03/17/16
20160075793 

Antigen binding molecules with increased fc receptor binding affinity and effector function


The present invention relates to antigen binding molecules (abms). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human cd20.
Roche Glycart Ag


03/17/16
20160075790 

Antibody polypeptides that antagonize cd40l


Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Bristol-myers Squibb Company


03/17/16
20160075789 

Anti-ectodysplasin antibodies


The present invention relates to the preparation of substantially purified anti-eda1 monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as pharmaceutical compositions containing such antibodies. The antibodies may be used in the treatment of disorders relating to excessive action of eda1 such as hirsutism, ectopic teeth, hyperhidrosis, breast cancer, dermal eccrine cylindroma or skin disorders such as sebaceous gland hyperplasia, comedones, milia, acne, seborrhea, rosacea, steatoma, and furuncles.
Edimer Pharmaceuticals, Inc.


03/17/16
20160075787 

Anti-cll-1 antibodies and immunoconjugates


The invention provides anti-cll-1 antibodies and immunoconjugates and methods of using the same.. .
Genentech, Inc.


03/17/16
20160075783 

Antibodies directed against programmed death-1 (pd-1)


The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (pd-1) protein. The invention provides a pd-1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide.
Anaptysbio, Inc.


03/17/16
20160075782 

Human monoclonal antibodies to programmed death ligand 1 (pd-l1)


The present disclosure provides isolated monoclonal antibodies particularly human monoclonal antibodies that specifically bind to pd-l1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E.r. Squibb & Sons, L. L. C.


03/17/16
20160075781 

Folate receptor 1 antibodies and immunoconjugates and uses thereof


Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided..
Immunogen, Inc.


03/17/16
20160075779 

Dll3 modulators and methods of use


Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. .
Stemcentrx, Inc.


03/17/16
20160075778 

Anti-glucagon antibodies and uses thereof


The present invention provides antibodies that bind to glucagon and methods of using the same. According to certain embodiments, the antibodies of the invention bind human gcg with high affinity.
Regeneron Pharmaceuticals, Inc.


03/17/16
20160075776 

Compositions and methods for controlled release of agents


This invention discloses reservoirs, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies. The reservoirs may comprise a porous silicon-based carrier material impregnated with the therapeutic agent.

03/17/16
20160075775 

Treatment of traumatic brain injury using antibodies to lysophosphatidic acid


Methods are provided for treating neurotrauma, for example, traumatic brain injury (tbi), using antibodies and antibody fragments that bind lysophosphatidic acid (lpa). Such treatment may result in functional locomotor recovery in subjects so treated, as well as reducing the size of a brain infarct in subjects having or suspected of having sustained neurotrauma such a tbi..
Lpath, Inc.


03/17/16
20160075773 

Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration


The present application describes rgm a binding proteins, particularly monoclonal antibodies, and in particular cdr grafted, humanized versions thereof, which have the ability to bind to rgm a and prevent binding of rgm proteins to rgm a receptor and other rgm a binding proteins, and therefore neutralize the function of rgm a, for use in the treatment of retinal nerve fiber layer (rnfl) degeneration as well as methods of therapeutically or prophylactically treating a mammal against rnfl degeneration.. .
Abbvie Deutschland Gmbh & Co. Kg


03/17/16
20160075772 

Treatment of fibrodysplasia ossificans progressiva


Methods for treating fibrodysplasia ossificans progressiva (fop) are provided. Such methods involve administering to a subject having fop an effective regime of an activin receptor type 2a (acvr2a) and/or an activin receptor type 2b (acvr2b) antagonist or an activin receptor type 1 (acvr1) antagonist.
Regeneron Pharmaceuticals, Inc.


03/17/16
20160075771 

Methods for treating neoplasia


The invention provides therapeutic methods featuring the use of chimeric human/mouse antibodies for the treatment of neoplasia.. .
Zestagen, S.a.


03/17/16
20160075770 

Composition with reduced immunogenicity


The present invention relates to a composition comprising polyclonal antibodies directed against human cells, wherein the said polyclonal antibodies are devoid of a first antigenic determinant selected in a group comprising (i) n-glycol-neuraminic acid (neu5gc) and (ii) α-1,3-galactose and its use as a medicament. .
Institut National De La Sante Et De La Recherche Medicale


03/17/16
20160075769 

Agrochemical compositions comprising antibodies binding to sphingolipids


The present invention relates to agrochemical and biological control compositions for combating pests, more specifically plant pests, comprising at least one polypeptide, which specifically binds to a pest. The invention further provides methods for protecting or treating a plant or a part of a plant from an infection or other biological interaction with a plant pathogen, at least comprising the step of applying directly or indirectly to a plant or to a part of a plant, an agrochemical composition, under conditions effective to protect or treat a plant or a part of a plant against a infection or biological interaction with a plant pathogen.
Agrosavfe N.v.


03/17/16
20160075768 

Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs


antibodies to seb, fragments thereof, and compositions comprising such are provided. Therapies for staphylococcal infection are provided, as well as assays for identifying additional agents useful in such therapies.
Albert Einstein College Of Medicine, Inc.


03/17/16
20160075766 

Method for producing antibodies using ovine b-cells and uses thereof


Herein is reported a cultivation system for cultivating a pool of ovine b-cells or single deposited ovine b-cells in the presence of phorbol myristate acetate (pma).. .
Roche Diagnostics Operations, Inc.


03/17/16
20160075734 

Peptoid affinity ligands


And shorter variants thereof are described, along with solid supports having such compounds coupled thereto, and the use thereof as affinity ligands for antibodies.. .



Antibodies topics: Antibodies, Recombinant, Nucleic Acid, Nucleic Acids, Polypeptide, Therapeutics, Immunoglobulin, Immunoglobulins, Monoclonal, Radiation Therapy, Desmoplastic, Hypertension, Hypertensive, Immunotherapy, Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antibodies for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibodies with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.2255

5045

2 - 1 - 109